Is cabozantinib a domestically produced or imported drug? Is it included in medical insurance?

Cabozantinib (Cabozantinib), whose trade names include Cometriq and Cabometyx, is an imported anti-tumor drug developed by the American Exelixis biopharmaceutical company. At present, cabozantinib has not been officially launched in China, so it cannot be included in domestic medical insurance reimbursement items. This situation limits the possibility for domestic patients to obtain the drug directly through medical insurance channels.

Cabozantinib is known for its multi-target, broad-spectrum anti-tumor properties. It can inhibit the activity of multiple receptor tyrosine kinases, includingVEGFR, MET and RET. These receptors play an important role in tumor growth, metastasis and angiogenesis. Therefore, cabozantinib has shown significant efficacy in the treatment of various solid tumors, such as kidney cancer, thyroid cancer, liver cancer, etc.

There are two main dosage forms of Cabozantinib on the market: capsule form (Cometriq) and tablet form (Cabometyx). Although both dosage forms contain the same active ingredient, cabozantinib, they differ in their formulation, use, and bioavailability.

Capsule dosage form (Cometriq): mainly used to treat medullary thyroid cancer, its specifications include 20mg and 80mg. This dosage form has shown good therapeutic effects in specific patient groups.

Tablet form (Cabometyx): For the treatment of renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer, specifications include 20mg, 40mg and 60mg. Tablet dosage forms may have superior pharmacokinetic properties and therapeutic efficacy compared with capsule dosage forms in certain patient populations.

It is important to note that due to the different formulations of the brands Cometriq and Cabometyx, they have differences in bioavailability, dosage, and mode of administration and therefore cannot be used interchangeably. When patients change dosage forms, they should adjust the dosage under the guidance of a doctor to ensure therapeutic effect and safety.

To sum up, cabozantinib, as an imported anti-tumor drug, has not yet been marketed in China and has not been included in the medical insurance reimbursement items. Its unique multi-target, broad-spectrum anti-tumor properties enable it to show broad prospects in the treatment of a variety of solid tumors. However, when patients choose to use cabozantinib, they should fully understand its dosage form, uses and precautions, and use it rationally under the guidance of a professional doctor.